AI in transportation

Showing 3466 articles
Business

Aon Posts Strong 2025, Eyes Steady Growth Amid Strategic Push

The global professional services firm reported sustained organic revenue growth and margin expansion for 2025, backed by its '3x3' strategic plan and technology investments. Leadership provided an upbeat outlook for 2026, targeting continued mid-single-digit growth and further profitability gains.

Business

W. P. Carey's Valuation Conundrum: A Deep Dive After a 31% Surge

Shares of diversified REIT W. P. Carey have delivered a robust 31% return over the past year, prompting investors to question whether the current price near $69 represents fair value or an opportunity. A closer look reveals a complex picture where traditional metrics and cash flow models tell conflicting stories.

Business

Benchmark Names T-Mobile (TMUS) a 2026 Best Idea

T-Mobile US Inc. (NASDAQ:TMUS) ranks among the most promising QQQ stocks according to hedge funds. On January 21, Benchmark reaffirmed its Buy rating on T-Mobile US Inc. (NASDAQ:TMUS) with a $295 price target, classifying the telecom provider as a “2026 Benchmark Best Idea.” The firm remains confident that T-Mobile’s network strengths and potential for expanded […]

Business

Carnival Stock: A Deep Value Play After Debt Pivot and Travel Rebound?

Carnival Corporation's shares have surged over three years, yet a detailed financial analysis suggests the cruise giant may still be trading at a significant discount. As the industry navigates post-pandemic recovery and debt reduction, investors are weighing if the current price reflects underlying value or lingering risks.

Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.